Key regions: Brazil, India, Australia, United States, United Kingdom
Antiviral drugs have become a vital part of the healthcare industry in Egypt. The market has been growing steadily over the years due to various reasons.
Customer preferences: Customers in Egypt have become more aware of the benefits of antiviral drugs. The demand for these drugs has increased due to the rise in viral infections in the country. The customers are also looking for affordable drugs that can help them fight infections.
Trends in the market: One of the major trends in the antiviral drugs market in Egypt is the increase in the number of local manufacturers. This has led to a decrease in the price of drugs, making them more affordable for customers. The market has also seen an increase in the number of generic drugs, which has further contributed to the affordability of these drugs.Another trend in the market is the shift towards combination therapies. Combination therapies involve the use of two or more drugs to treat a viral infection. This approach has become popular in Egypt due to its effectiveness in treating viral infections.
Local special circumstances: Egypt has a high prevalence of viral infections such as hepatitis C and HIV. This has led to a high demand for antiviral drugs in the country. The government has also taken steps to increase access to these drugs by providing subsidies to patients.
Underlying macroeconomic factors: The Egyptian government has been investing heavily in the healthcare sector, which has contributed to the growth of the antiviral drugs market. The country has also seen an increase in foreign investment, which has led to the development of new drugs and therapies.In conclusion, the antiviral drugs market in Egypt has been growing steadily due to the high demand for these drugs. The increase in local manufacturers and the shift towards combination therapies has made these drugs more affordable for customers. The government's investment in the healthcare sector and the increase in foreign investment has also contributed to the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
